Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Nov 16;5:939–948. doi: 10.2147/vhrm.s7263

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 Verdecchia et al, publisher and licensee Dove Medical Press Ltd.

This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

PMC Copyright notice

Major trials with angiotensin receptor blockers in specific cardiovascular conditions.

Abbreviations: CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity; ELITE, evaluation of Losartan in the elderly; I-PRESERVE, Irbesartan in Heart Failure with Preserved Ejection Fraction Study; IRMA, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria; LIFE, Losartan intervention for End Point Reduction; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; OPTIMAAL, Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan; RENAAL, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; SCOPE, Study on Cognition and Prognosis in the Elderly; VALIANT, Valsartan in Acute Myocardial infarction; Val-HEFT, Valsartan Heart Failure Trial; VALUE, Valsartan Antihypertensive Long-term Use Evaluation.